Mauricio Osorio

I run FuturWeightLoss.com, an independent research and review platform covering GLP-1 medications (semaglutide, tirzepatide), telehealth weight loss programs, and compounded medication access. I track the evolving landscape of GLP-1 prescribing, compounding regulations, patient outcomes, and telehealth platform quality — including the FDA's April 2026 proposed restrictions on 503B compounding. My work focuses on helping patients make informed decisions about Ozempic alternatives, compounded semaglutide vs brand-name options, tirzepatide access and pricing, and choosing between telehealth platforms. I follow clinical trial data (STEP and SURMOUNT programs), FDA regulatory developments, and real patient outcomes across the major GLP-1 telehealth providers. I am available to comment on: ...